DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 937 filers reported holding DANAHER CORPORATION in Q4 2014. The put-call ratio across all filers is 0.82 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $233 | -100.0% | 938 | -99.0% | 0.01% | -98.7% |
| Q1 2020 | $13,382,000 | +395.4% | 96,683 | +449.4% | 0.82% | +2828.6% |
| Q4 2019 | $2,701,000 | -95.8% | 17,597 | -96.0% | 0.03% | -94.6% |
| Q3 2019 | $64,195,000 | +28.9% | 444,468 | +27.5% | 0.52% | +48.7% |
| Q2 2019 | $49,813,000 | +16.8% | 348,539 | +7.9% | 0.35% | -18.6% |
| Q1 2019 | $42,644,000 | +67.8% | 323,014 | +31.0% | 0.43% | +55.6% |
| Q4 2018 | $25,418,000 | +4.4% | 246,490 | +10.0% | 0.28% | +20.4% |
| Q3 2018 | $24,339,000 | +52.7% | 223,992 | +38.7% | 0.23% | +41.1% |
| Q2 2018 | $15,934,000 | +25.8% | 161,468 | +24.8% | 0.16% | +15.6% |
| Q1 2018 | $12,670,000 | +10.1% | 129,405 | +4.4% | 0.14% | -1.4% |
| Q4 2017 | $11,509,000 | -4.8% | 123,993 | -12.0% | 0.14% | -10.1% |
| Q3 2017 | $12,091,000 | +58.2% | 140,952 | +55.6% | 0.16% | +24.2% |
| Q2 2017 | $7,644,000 | -56.9% | 90,579 | -56.3% | 0.13% | -51.3% |
| Q1 2017 | $17,742,000 | +126.3% | 207,439 | +105.9% | 0.26% | +128.7% |
| Q4 2016 | $7,840,000 | +43.0% | 100,724 | +44.0% | 0.12% | +30.7% |
| Q3 2016 | $5,482,000 | -59.1% | 69,932 | -47.3% | 0.09% | -2.2% |
| Q2 2016 | $13,397,000 | +173.3% | 132,648 | +156.7% | 0.09% | +119.5% |
| Q1 2016 | $4,902,000 | -29.6% | 51,679 | -31.1% | 0.04% | -24.1% |
| Q4 2015 | $6,968,000 | +106.9% | 75,018 | +89.8% | 0.05% | +116.0% |
| Q3 2015 | $3,367,000 | -64.3% | 39,518 | -64.1% | 0.02% | -49.0% |
| Q2 2015 | $9,419,000 | -42.7% | 110,047 | -43.2% | 0.05% | -50.5% |
| Q1 2015 | $16,447,000 | +17.5% | 193,725 | +18.6% | 0.10% | +11.2% |
| Q4 2014 | $13,997,000 | -7.5% | 163,305 | -18.0% | 0.09% | +45.9% |
| Q3 2014 | $15,124,000 | +23.7% | 199,048 | +28.2% | 0.06% | -1.6% |
| Q2 2014 | $12,225,000 | -2.0% | 155,274 | -6.6% | 0.06% | +14.8% |
| Q1 2014 | $12,475,000 | +1.6% | 166,331 | +0.8% | 0.05% | -10.0% |
| Q4 2013 | $12,275,000 | -14.0% | 165,008 | -19.9% | 0.06% | -15.5% |
| Q3 2013 | $14,272,000 | -5.0% | 205,890 | -13.2% | 0.07% | +7.6% |
| Q2 2013 | $15,022,000 | – | 237,316 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |